

# David F Claxton

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2016632/publications.pdf>

Version: 2024-02-01

85  
papers

2,059  
citations

331670

21  
h-index

254184

43  
g-index

86  
all docs

86  
docs citations

86  
times ranked

3539  
citing authors

#	ARTICLE	IF	CITATIONS
1	Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1&acirc2 study. <i>Lancet Oncology</i> , 2017, 18, 1061-1075.	10.7	402
2	A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. <i>Blood</i> , 2019, 133, 1548-1559.	1.4	292
3	T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell Exhaustion and Poor Clinical Outcome in AML Patients. <i>Clinical Cancer Research</i> , 2016, 22, 3057-3066.	7.0	217
4	VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML. <i>Oncolmmunology</i> , 2018, 7, e1469594.	4.6	107
5	Acid ceramidase is upregulated in AML and represents a novel therapeutic target. <i>Oncotarget</i> , 2016, 7, 83208-83222.	1.8	73
6	Atg5-dependent autophagy contributes to the development of acute myeloid leukemia in an MLL-AF9-driven mouse model. <i>Cell Death and Disease</i> , 2016, 7, e2361-e2361.	6.3	51
7	Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients. <i>Blood Cancer Journal</i> , 2018, 8, 34.	6.2	48
8	Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2017, 10, 124.	17.0	42
9	Eomes+T-betlow CD8+ T Cells Are Functionally Impaired and Are Associated with Poor Clinical Outcome in Patients with Acute Myeloid Leukemia. <i>Cancer Research</i> , 2019, 79, 1635-1645.	0.9	42
10	Frontline-Treatment Of Acute Lymphoblastic Leukemia (ALL) In Older Adolescents and Young Adults (AYA) Using a Pediatric Regimen Is Feasible: Toxicity Results of the Prospective US Intergroup Trial C10403 (Alliance). <i>Blood</i> , 2013, 122, 3903-3903.	1.4	35
11	Final Results of the Chrysalis Trial: A First-in-Human Phase 1/2 Dose-Escalation, Dose-Expansion Study of Gilteritinib (ASP2215) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML). <i>Blood</i> , 2016, 128, 1069-1069.	1.4	35
12	Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies. <i>Cell Cycle</i> , 2018, 17, 468-478.	2.6	34
13	Maritoclax induces apoptosis in acute myeloid leukemia cells with elevated Mcl-1 expression. <i>Cancer Biology and Therapy</i> , 2014, 15, 1077-1086.	3.4	33
14	Acid ceramidase promotes drug resistance in acute myeloid leukemia through NF-ÎB-dependent P-glycoprotein upregulation. <i>Journal of Lipid Research</i> , 2019, 60, 1078-1086.	4.2	31
15	Genome-wide mapping of histone H3K9me2 in acute myeloid leukemia reveals large chromosomal domains associated with massive gene silencing and sites of genome instability. <i>PLoS ONE</i> , 2017, 12, e0173723.	2.5	29
16	Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia. <i>Blood Advances</i> , 2021, 5, 504-512.	5.2	28
17	HOXBLOC long non-coding RNA activation promotes leukemogenesis in NPM1-mutant acute myeloid leukemia. <i>Nature Communications</i> , 2021, 12, 1956.	12.8	28
18	SKI-178: A multitargeted inhibitor of sphingosine kinase and microtubule dynamics demonstrating therapeutic efficacy in acute myeloid leukemia models. <i>Cancer Translational Medicine</i> , 2017, 3, 109.	0.2	27

#	ARTICLE	IF	CITATIONS
19	Downregulation of CD73 associates with T cell exhaustion in AML patients. <i>Journal of Hematology and Oncology</i> , 2019, 12, 40.	17.0	25
20	Modification of sphingolipid metabolism by tamoxifen and N-desmethyltamoxifen in acute myelogenous leukemia—Impact on enzyme activity and response to cytotoxics. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2015, 1851, 919-928.	2.4	24
21	Sphingolipid metabolism determines the therapeutic efficacy of nanoliposomal ceramide in acute myeloid leukemia. <i>Blood Advances</i> , 2019, 3, 2598-2603.	5.2	24
22	Post-transplant cyclophosphamide alters immune signatures and leads to impaired T cell reconstitution in allogeneic hematopoietic stem cell transplant. <i>Journal of Hematology and Oncology</i> , 2022, 15, 64.	17.0	24
23	Ceramide Analogue SACLAC Modulates Sphingolipid Levels and <i>MCL-1</i> Splicing to Induce Apoptosis in Acute Myeloid Leukemia. <i>Molecular Cancer Research</i> , 2020, 18, 352-363.	3.4	22
24	Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin. <i>Journal of Clinical Oncology</i> , 2021, 39, 1001-1009.	1.6	22
25	Maintenance Decitabine (DAC) Improves Disease-Free (DFS) and Overall Survival (OS) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults, Particularly in FLT3-ITD-Negative Patients: ECOG-ACRIN (E-A) E2906 Randomized Study. <i>Blood</i> , 2019, 134, 115-115.	1.4	19
26	Therapeutic inhibition of BCL-2 and related family members. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 293-301.	4.1	18
27	Glucocorticoids enhance the antileukemic activity of FLT3 inhibitors in FLT3-mutant acute myeloid leukemia. <i>Blood</i> , 2020, 136, 1067-1079.	1.4	18
28	Schweinfurthin natural products induce regression of murine melanoma and pair with anti-PD-1 therapy to facilitate durable tumor immunity. <i>OncImmunology</i> , 2019, 8, e1539614.	4.6	17
29	Clofarabine, Etoposide and Mitoxantrone In the Therapy of Relapsed and Refractory Acute Myelogenous Leukemia. <i>Blood</i> , 2010, 116, 4353-4353.	1.4	17
30	A phase I clinical trial of avelumab in combination with decitabine as first line treatment of unfit patients with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2021, 96, E46-E50.	4.1	16
31	Toxicities and Outcomes of Ibrutinib-Treated Patients in the United States: Large Retrospective Analysis of 621 Real World Patients. <i>Blood</i> , 2016, 128, 3222-3222.	1.4	16
32	The novel Isatin analog KS99 targets stemness markers in acute myeloid leukemia. <i>Haematologica</i> , 2020, 105, 687-696.	3.5	14
33	The PI3K/AKT Pathway Inhibitor ISC-4 Induces Apoptosis and Inhibits Growth of Leukemia in Preclinical Models of Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2020, 10, 393.	2.8	14
34	Therapy of acute myeloid leukemia: therapeutic targeting of tyrosine kinases. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 337-349.	4.1	13
35	Multi-Dimensional Analysis of Immune Signature Predicts Response to Decitabine Treatment in Elderly Patients with AML. <i>Blood</i> , 2018, 132, 1526-1526.	1.4	13
36	Multi-dimensional analysis identifies an immune signature predicting response to decitabine treatment in elderly patients with AML. <i>British Journal of Haematology</i> , 2020, 188, 674-684.	2.5	12

#	ARTICLE	IF	CITATIONS
37	AML chemoresistance: The role of mutant TP53 subclonal expansion and therapy strategy. <i>Experimental Hematology</i> , 2020, 87, 13-19.	0.4	12
38	Mechanistic Basis for In Vivo Therapeutic Efficacy of CK2 Inhibitor CX-4945 in Acute Myeloid Leukemia. <i>Cancers</i> , 2021, 13, 1127.	3.7	12
39	Extracts of Devil's Club ( <i>Oplopanax horridus</i> ) Exert Therapeutic Efficacy in Experimental Models of Acute Myeloid Leukemia. <i>Phytotherapy Research</i> , 2014, 28, 1308-1314.	5.8	9
40	Phase I/II Study of Clofarabine, Etoposide, and Mitoxantrone in Patients With Refractory or Relapsed Acute Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 41-46.	0.4	9
41	PIGN gene expression aberration is associated with genomic instability and leukemic progression in acute myeloid leukemia with myelodysplastic features. <i>Oncotarget</i> , 2017, 8, 29887-29905.	1.8	9
42	Impact of ruxolitinib on myelofibrosis patients post allogeneic stem cell transplant—a pilot study. <i>British Journal of Haematology</i> , 2019, 186, e130-e133.	2.5	9
43	Harnessing the power of sphingolipids: Prospects for acute myeloid leukemia. <i>Blood Reviews</i> , 2022, 55, 100950.	5.7	9
44	Acute Myeloid Leukemia Stem Cells: Origin, Characteristics, and Clinical Implications. <i>Stem Cell Reviews and Reports</i> , 2022, 18, 1211-1226.	3.8	8
45	Therapeutic effect of Northern Labrador tea extracts for acute myeloid leukemia. <i>Phytotherapy Research</i> , 2018, 32, 1636-1641.	5.8	7
46	Final Results of a Phase 1-2 Study of Vorinostat (SAHA), Cladribine, and Rituximab (SCR) Relapsed B-Cell Non-Hodgkin's Lymphoma and Previously Untreated Mantle Cell Lymphoma. <i>Blood</i> , 2014, 124, 1714-1714.	1.4	7
47	Alterations in sphingolipid composition and mitochondrial bioenergetics represent synergistic therapeutic vulnerabilities linked to multidrug resistance in leukemia. <i>FASEB Journal</i> , 2022, 36, e22094.	0.5	7
48	Interleukin-4 treatment reduces leukemia burden in acute myeloid leukemia. <i>FASEB Journal</i> , 2022, 36, e22328.	0.5	7
49	Results of a Phase 3 Study of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles. <i>Blood</i> , 2017, 130, 891-891.	1.4	6
50	TIGIT Expression Positively Associates with NK Cell Function in AML Patients. <i>Blood</i> , 2018, 132, 5250-5250.	1.4	5
51	Feasibility of Allogeneic Hematopoietic Cell Transplantation Among High-Risk AML Patients in First Complete Remission: Results of the Transplant Objective from the SWOG (S1203) Randomized Phase III Study of Induction Therapy Using Standard 7+3 Therapy or Idarubicin with High-Dose Cytarabine (IA) Versus IA Plus Vorinostat. <i>Blood</i> , 2016, 128, 1166-1166.	1.4	5
52	The Results of a Phase I Study using Velcade (Bortezomib), Cladribine, and Rituximab (VCR) in treating Mantle Cell Lymphoma. <i>Blood</i> , 2016, 128, 1792-1792.	1.4	5
53	Therapeutic Effect of Blueberry Extracts for Acute Myeloid Leukemia. , 2018, 1, .		5
54	Maximal Tolerated Dose Determined for Venetoclax in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory Ph-Negative T-Cell or B-Cell Acute Lymphoblastic Leukemia: Results of Phase 1 Portion of ECOG-ACRIN EA9152. <i>Blood</i> , 2021, 138, 3407-3407.	1.4	5

#	ARTICLE	IF	CITATIONS
55	A novel clinically relevant graft-versus-leukemia model in humanized mice. <i>Journal of Leukocyte Biology</i> , 2022, 111, 427-437.	3.3	4
56	Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS). <i>Cancer</i> , 2021, 127, 4421-4431.	4.1	4
57	DJ4 Targets the Rho-Associated Protein Kinase Pathway and Attenuates Disease Progression in Preclinical Murine Models of Acute Myeloid Leukemia. <i>Cancers</i> , 2021, 13, 4889.	3.7	4
58	Minimal Residual Disease (MRD) at Time of Complete Remission Is Commonly Detected in Acute Myeloid Leukemia (AML) Patients Age $\geq 60$ Years and Significantly Impacts Outcome Based on Post-Remission Treatment Strategies: Prospective Analysis of ECOG-ACRIN (E-A) E2906 Phase III Trial. <i>Blood</i> , 2018, 132, 437-437.	1.4	4
59	Engraftment of Human Primary Acute Myeloid Leukemia Defined by Integrated Genetic Profiling in NOD/SCID/IL2r $\beta$ null Mice for Preclinical Ceramide-Based Therapeutic Evaluation. <i>Journal of Leukemia (Los Angeles, Calif)</i> , 2014, 02, .	0.1	3
60	FLT3-ITD Mutations Are Prevalent and Significantly Impact Outcome after Intensive Therapy in Elderly Adults with Acute Myeloid Leukemia (AML): Analysis of the North American Intergroup E2906 Phase III Trial in Patients Age $\geq 60$ Years. <i>Blood</i> , 2018, 132, 3995-3995.	1.4	3
61	Combinatorial Efficacy of Quercetin and Nanoliposomal Ceramide for Acute Myeloid Leukemia. , 2018, 1, .		3
62	Autologous immunotherapy for human leukemias. <i>Blood Cells, Molecules, and Diseases</i> , 2003, 31, 121-124.	1.4	2
63	Myeloid Sarcoma of the Thyroid. <i>Ear, Nose and Throat Journal</i> , 2017, 96, 460-461.	0.8	2
64	Improved outcome in AML relapse after allogeneic transplant with high-intensity chemotherapy followed by 2nd allogeneic stem cell transplant or donor lymphocyte infusion. <i>Annals of Hematology</i> , 2021, 100, 2585-2592.	1.8	2
65	Effect of Avelumab to Immune Response in AML: A Phase I Study of Avelumab in Combination with Decitabine As First Line Treatment of Unfit Patients. <i>Blood</i> , 2019, 134, 3939-3939.	1.4	2
66	Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax in CLL: Results from a Large Multi-Center Study of 683 US-Patients. <i>Blood</i> , 2016, 128, 4400-4400.	1.4	2
67	Intractable myoclonic seizures in an allogeneic stem cell transplant recipient: A rare case of myoclonic epilepsy. <i>Epilepsy &amp; Behavior Case Reports</i> , 2015, 4, 48-51.	1.5	1
68	Vorinostat (SAHA), Cladribine, and Rituximab in Previously Untreated Mantle Cell Lymphoma: Updated Results From a Phase I/II Trial. <i>Blood</i> , 2012, 120, 3675-3675.	1.4	1
69	Single Agent and Combinatorial Efficacy of First-in-Class Small Molecule ONC201 in Acute Leukemia and Multiple Myeloma. <i>Blood</i> , 2016, 128, 2759-2759.	1.4	1
70	Genome-wide mapping of large organized heterochromatin domains reveals hotspots of epigenetic and transcriptional changes associated with myeloid differentiation and acute myeloid leukemia (565.1). <i>FASEB Journal</i> , 2014, 28, 565.1.	0.5	1
71	An Integrated Framework for Genome Analysis Reveals Numerous Previously Unrecognizable Structural Variants in Leukemia Patient Samples. <i>FASEB Journal</i> , 2019, 33, 474.1.	0.5	1
72	Allogeneic Transplantation in Fit Older Adults Is Feasible and Encouragingly Efficacious. Post Remission Data from the Prospective ECOG-ACRIN (E2906) Clinical Study. <i>Blood</i> , 2021, 138, 413-413.	1.4	1

#	ARTICLE	IF	CITATIONS
73	Out Foxing Bcr-Abl. <i>Cancer Biology and Therapy</i> , 2011, 11, 769-770.	3.4	0
74	Successful Treatment of Advanced and Refractory AML with Sirolimus Based Non-Myeloablative Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2004, 104, 2760-2760.	1.4	0
75	Non-Myeloablative Hematopoietic Transplant with Sirolimus Immunosuppression: Determinants of Outcome.. <i>Blood</i> , 2005, 106, 5462-5462.	1.4	0
76	Sirolimus as Primary Immunoprophylaxis for Alternative Donor Allograft after Non-Myeloablative Conditioning.. <i>Blood</i> , 2007, 110, 3069-3069.	1.4	0
77	Potent Anti-Leukemic Activity of a Cationic Lipid-DNA Complex.. <i>Blood</i> , 2007, 110, 4891-4891.	1.4	0
78	Early Discharge and Out Patient Management After AML Induction Chemotherapy: Determinants of Safety. <i>Blood</i> , 2012, 120, 2054-2054.	1.4	0
79	Enhancing Ceramide Cytotoxicity in Acute Myelogenous Leukemia. <i>Blood</i> , 2012, 120, 4905-4905.	1.4	0
80	The Novel Small Molecule Inhibitor KS99 Targets AML and Inhibits Stemness Markers STAT3 and ALDH. <i>Blood</i> , 2018, 132, 1440-1440.	1.4	0
81	Non-Myeloablative Allogeneic Stem Cell Transplant in Acute Myeloid Leukemia: Graft-Versus-Host Disease Potentiates Graft-Versus-Leukemia Effect and Improves Overall Survival. <i>Blood</i> , 2019, 134, 5724-5724.	1.4	0
82	Engraftment Kinetics and Recipient Chimerism Increase to Predict Leukemia Relapse By Ptcy and Non-Ptcy Transplant. <i>Blood</i> , 2021, 138, 1792-1792.	1.4	0
83	DJ4 Targets Rho-associated Protein Kinase Pathway and Attenuates Disease Progression in Pre-clinical Murine Models of Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 3350-3350.	1.4	0
84	<i>Hottip</i>-Mediated R-Loops Regulate CTCF TAD Boundary to Control WNT/b-Catenin Pathway in AML Genome. <i>Blood</i> , 2020, 136, 44-45.	1.4	0
85	Clonal haematopoiesis as a risk factor for therapy-related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo-immunotherapy. <i>British Journal of Haematology</i> , 2022, , .	2.5	0